29 evaluations were analysed, of which 23 (79%) recommended for funding. Six main sources of insecurity have been identified. The immaturity of survival data and comparator-related issues were frequent sources of uncertainty, regardless of the degree of concern. Uncertainties regarding the quality of life and patient population in the study were frequently discussed, but rarely appeared in more uncertain assessments. Concerns about trial planning and cost uncertainty were less frequent, but a significant proportion contributed to the most uncertain assessments. Funding decisions were not motivated by the uncertainty of the database, but by the costs expected by QALY relative to the acceptance thresholds and the degree of uncertainty that resulted in the decision. That`s nice. PMG19 Addendum has – the latest changes to THE procedures and methods of evaluating NICE technologies Guidelines in support of the proposed new rules for the Cancer Drug Fund. www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/process-and-methods-guide-addendum.pdf, 2016. Palbociclib with aromatase inhibitors for untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic receptors (TA495) 2017.
www.nice.org.uk/guidance/ta495. “The committee accepted that this ICE IC was related to uncertainty, but in the end it was convinced that it would remain below $30,000 per QALY obtained” (Enzalutamide for Prostate Cancer ) We cannot apply directly. Your cancer specialist is in the best position to suggest which treatment is best for you. You make a decision based on: NICE. Erlotinib and gefitinib for the treatment of advanced non-small cell lung cancer after previous chemotherapy (TA374) 2015. www.nice.org.uk/guidance/ta374. The Parliamentary Office for Science and Technology. Assessment based on the value of drugs. researchbriefings.files.parliament.uk/documents/POST-PN-487/POST-PN-487.pdf.
Grieve R, Abrams K, Claxton K, Goldacre B, James N, Nicholl J, et al. The Cancer Drug Fund is in need of further reform. Bmj. 2016;354:i5090. That`s nice. Ramucirumab for the treatment of advanced stomach cancer or gastroesophageal cross-esophageal cancer previously treated with chemotherapy (TA378) 2016. www.nice.org.uk/guidance/ta378. The expenditure control mechanism ensures that the CDF does not spend too much. This will ensure that the Fund remains open to eligible new patients. You`ll find the latest update to CDF activities and editions in the CDF activity update. That`s nice. Olaparib for the maintenance of ovarian, tubal and peritoneal cancers, sanitizing, platinum-sensitive, BRCA mutation, after reaction to a second platinum-based chemotherapy (TA381) 2016.
www.nice.org.uk/guidance/ta381. In 2016, it was reformed as a managed access fund. Drugs with clinical potential may be provided temporarily by the CDF, in cases where NICE does not yet provide definitive guidelines or where there is insufficient evidence to be properly evaluated. It is also possible to decide how long a drug should remain on the cancer fund list. Most drugs only stay in CDF for a short period of time.